Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

ClinicalTrials.gov ID: NCT02855164

Public ClinicalTrials.gov record NCT02855164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Study identification

NCT ID
NCT02855164
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
350 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2016
Primary completion
Apr 5, 2020
Completion
Apr 5, 2020
Last update posted
Sep 4, 2021

2016 – 2020

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Novartis Investigative Site Madison Alabama 35758
Novartis Investigative Site North Little Rock Arkansas 72117
Novartis Investigative Site Coronado California 92118
Novartis Investigative Site Los Angeles California 90057
Novartis Investigative Site Pasadena California 91105
Novartis Investigative Site Rialto California 92377
Novartis Investigative Site San Diego California 92114
Novartis Investigative Site San Francisco California 94115
Novartis Investigative Site Lonetree Colorado 80124
Novartis Investigative Site Boca Raton Florida 33434
Novartis Investigative Site Jacksonville Florida 32256
Novartis Investigative Site Lakewood Rch Florida 34211
Novartis Investigative Site Miami Florida 33136
Novartis Investigative Site Orlando Florida 32806
Novartis Investigative Site Pensacola Florida 32503
Novartis Investigative Site Athens Georgia 30607
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site Catonsville Maryland 21228
Novartis Investigative Site Worcester Massachusetts 01655
Novartis Investigative Site Detroit Michigan 48202
Novartis Investigative Site Minneapolis Minnesota 55455
Novartis Investigative Site Jefferson City Missouri 65109
Novartis Investigative Site Berlin New Jersey 08009
Novartis Investigative Site Morehead City North Carolina 28557
Novartis Investigative Site Cincinnati Ohio 45219
Novartis Investigative Site Hermitage Tennessee 37076
Novartis Investigative Site Dallas Texas 75208-2312
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site San Antonio Texas 78215
Novartis Investigative Site Norfolk Virginia 23502
Novartis Investigative Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02855164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 4, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02855164 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →